Wed Aug 31, 2022 – 5:26 pm EDT
SILVER SPRING, Maryland (LifeSiteNews) – The U.S. Food and Drug Administration (FDA) approved a request from Pfizer and Moderna for Emergency Use Authorization (EUA) for their new COVID-19 Omicron subvariant booster shots Wednesday.
FDA will likely authorize the Omicron vaccine later today/tomorrow based on data from 8 mice and no human clinical data avail to the public. Americans deserve to see the data. Why is the White House/Dr. Jha pushing it so hard & universally w/o public data? https://t.co/mfgyJnHOiv
— Marty Makary MD, MPH (@MartyMakary) August 31, 2022
In a statement released by the FDA, the agency stated that the boosters would be bivalent, or able to fight two strains of a disease, in this case both the original COVID strain and the BA.4 and BA.5 substrains of the Omicron variant, and are approved for single booster doses at least two months after receiving an initial jab or a booster. The agency also stated that Moderna’s booster would be available for adults ages 18 and older, and Pfizer’s booster would be available for anyone 12 and older.
FDA is recommending the new boosters just *TWO MONTHS*
The remainder of this article is available in its entirety at LifeSite News
The views expressed in this news alert by the author do not directly represent that of The Official Street Preachers or its editors
